#United States #New York #PTC Therapeutics #R&D Day #pipeline updates

PTC Therapeutics to Host R&D Day

PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced an important event for stakeholders and the general public. The company is set to host an R&D Day on December 2, 2025, at 9:30 a.m. EST in New York City. This event will serve as a platform for the company's leadership to present key updates on their current research pipeline, which focuses on innovative treatments for rare disorders.

Event Details

During the R&D Day, Dr. Matthew B. Klein, CEO of PTC Therapeutics, alongside members of the research and development teams, will provide insights into the company’s proprietary small molecule splicing and inflammation platforms. Attendees can expect detailed discussions surrounding new targets and ongoing programs. The event will also be webcast live, allowing for broader participation remotely.

Interested individuals can register for the webcast by visiting the Events and Presentations section on the Investor Relations page of the PTC Therapeutics website. An on-demand replay will be accessible for approximately 30 days following the live event, ensuring that the information presented can reach those who are unable to attend live.

About PTC Therapeutics, Inc.

PTC Therapeutics is a pioneering biopharmaceutical company focused on discovering, developing, and commercializing therapeutics intended for individuals suffering from rare and challenging disorders. The firm is committed to enhancing the quality of life for patients by advancing a diverse pipeline of transformative medicines, meticulously designed to cater to unmet medical needs.

The company employs its vast scientific knowledge and a robust commercial framework to optimize value for patients and stakeholders alike. PTC Therapeutics' mission emphasizes not only the delivery of state-of-the-art treatments but also ensuring accessibility across their patient demographic.

Over the past years, PTC Therapeutics has worked diligently to push the boundaries of innovation in the biopharmaceutical industry, resulting in significant advancements in therapies that can dramatically alter patient outcomes. The company's ongoing commitment to research and development remains steadfast, and this upcoming R&D Day is a testament to their dedication.

For further information about PTC Therapeutics, including its comprehensive pipeline and various media releases, you can explore their official website at www.ptcbio.com. Additionally, PTC Therapeutics is active on several social media platforms, including LinkedIn, X, Facebook, and Instagram, where they continue to engage with the community and disseminate valuable updates.

This R&D Day represents an unprecedented opportunity for investors, healthcare professionals, and advocates for rare diseases to gain critical insights into the advancements being made by PTC Therapeutics. As the company continues to make strides in addressing the needs of patients with rare disorders, the significance of events like these cannot be overstated. Mark your calendars for December 2, 2025, and stay tuned for more updates from this innovative biopharmaceutical provider!